What is the upside for ZIOPHARM Oncology stock?
On average, they expect ZIOPHARM Oncology's stock price to reach $6.88 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.
What are analysts'price targets for ZIOPHARM Oncology's stock?
4 analysts have issued 12-month price targets for ZIOPHARM Oncology's stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate ZIOPHARM Oncology's share price to reach $3.50 in the next twelve months.
Where can I buy shares of ziop?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What does ZIOPHARM Oncology do?
Something went wrong while loading Watchlist. ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer.
Will Ziop stock go up?
Based on analyst ratings, Ziopharm Oncology's 12-month average price target is $1.75. What is ZIOP's upside potential, based on the analysts' average price target? Currently there's no upside potential for ZIOP, based on the analysts' average price target.
Is Ziop a good stock?
(NASDAQ:ZIOP) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them.
When did ziopharm go public?
Founded in 2003 with a 2005 IPO, ZIOPHARM has since struggled to maintain a market cap of $603M (June 2021) with its 105 employees.
What happened to Ziop?
ZIOPHARM Oncology (NASDAQ:ZIOP) has rebranded itself and is now known as Alaunos Therapeutics. Along with the name change, the company said that a phase 1/2 IND was amended to include four additional t-cell receptor therapies (TCR-T), bring the total to 10.
Should I buy or sell ZIOPHARM Oncology stock right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 2 hold ra...
What is ZIOPHARM Oncology's stock price forecast for 2022?
3 brokers have issued 12-month price objectives for ZIOPHARM Oncology's shares. Their forecasts range from $2.00 to $3.50. On average, they expect...
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earni...
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the following people: Kevin S. Boyle , Chief Executive Officer & Director ( LinkedIn Profile ) Timo...
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron...
What other stocks do shareholders of ZIOPHARM Oncology own?
Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN) ,...
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Group One Trading L.P....
Which major investors are selling ZIOPHARM Oncology stock?
ZIOP stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Cutler Group LP, and Simplex Tra...
About ZIOPHARM Oncology
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T.
When will Ziopharm report results?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZIOPHARM Oncology stock.
When is Ziopharm conference call?
Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting...
Signals & Forecast
Most Recent Stories. Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial...
Support, Risk & Stop-loss
There are mixed signals in the stock today. The ZIOPHARM Oncology Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is ZIOPHARM Oncology Inc stock A Buy?
ZIOPHARM Oncology Inc finds support from accumulated volume at $0.86 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in ZIOPHARM Oncology Inc
ZIOPHARM Oncology Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About ZIOPHARM Oncology Inc
In the last 100 trades there were 11.87 million shares bought and 777.99 thousand shares sold. The last trade was done 66 days ago by De Groot Eleanor who sold 20.13 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
ZIOPHARM Oncology (NASDAQ:ZIOP) Price Target and Consensus Rating
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Analyst Ratings By Month
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
ZIOPHARM Oncology (NASDAQ:ZIOP) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
